How long does ARA-290 (Cibinetide) take to work?
In the first week of ARA-290 (Cibinetide), subtle. Some neuropathic pain users notice first nerve-tingling reduction. Around week 4, cumulative effect. Sarcoidosis trial endpoint. By week 8, sustained users see compounding benefits. Response varies between people, this is the commonly reported pattern, not a guarantee.
Week by week
- Week 1: Subtle. Some neuropathic pain users notice first nerve-tingling reduction.
- Week 4: Cumulative effect. Sarcoidosis trial endpoint.
- Week 8: Sustained users see compounding benefits.
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Last updated 2026-06-06.